Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, 610041, Sichuan, People's Republic of China.
Int Urol Nephrol. 2020 Jul;52(7):1243-1254. doi: 10.1007/s11255-020-02406-0. Epub 2020 Feb 20.
Currently, there is limited evidence comparing robot-assisted radical cystectomy (RARC) to laparoscopic radical cystectomy (LRC). The purpose of this study is to systematically review the literature and conduct a meta-analysis.
We conducted a systematic literature search to identify matching publications regarding RARC and LRC for bladder cancer through PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science with no restriction to date and language. The evaluated outcomes include perioperative outcomes (i.e. days to oral intake, operative time, estimated blood loss (EBL), transfusion rates, length of stay (LOS) and complication rates) and oncological outcomes (i.e. positive surgical margin (PSM), lymph node yield, and overall survival (OS)).
After screening 780 articles, 10 studies were included in the final meta-analysis. We found that there was no significant difference with regard to basic demographic variables, operative time, and PSM. There were statistically significant shorter LOS (MD - 0.63, 95% CI - 1.24, 0.03), fewer complication rates (the risk ratios were 0.74 and 0.49 for Clavien grade 1-2 and Clavien grade 3-5,respectively), more lymph node yield (MD 2.38, 95% CI 1.89-2.87) and less death risk (HR 0.26, 95% CI 0.17-0.39) in RARC group compared with LRC group.
Our findings indicated that patients with RARC may benefit from significantly lower complications, shorter LOS, higher lymph node yield and lower death risk. These data thus showed that RARC might improve the management of patients with muscle invasive or high-risk non-muscle invasive bladder cancer.
目前,比较机器人辅助根治性膀胱切除术(RARC)和腹腔镜根治性膀胱切除术(LRC)的证据有限。本研究的目的是系统地回顾文献并进行荟萃分析。
我们通过 PubMed/Medline、Embase、Cochrane 对照试验中心注册库(CENTRAL)和 Web of Science 进行了系统的文献检索,对膀胱癌的 RARC 和 LRC 匹配出版物进行了无日期和语言限制的检索。评估的结果包括围手术期结果(即口服摄入时间、手术时间、估计失血量(EBL)、输血率、住院时间(LOS)和并发症发生率)和肿瘤学结果(即阳性手术切缘(PSM)、淋巴结产量和总生存率(OS))。
在筛选了 780 篇文章后,有 10 项研究纳入了最终的荟萃分析。我们发现,基本人口统计学变量、手术时间和 PSM 方面没有显著差异。RARC 组的 LOS 更短(MD -0.63,95%CI -1.24,0.03)、并发症发生率更低(Clavien 1-2 级和 3-5 级的风险比分别为 0.74 和 0.49)、淋巴结产量更多(MD 2.38,95%CI 1.89-2.87)和死亡率更低(HR 0.26,95%CI 0.17-0.39)。
我们的研究结果表明,RARC 患者可能受益于并发症发生率显著降低、LOS 缩短、淋巴结产量增加和死亡率降低。这些数据表明,RARC 可能改善肌层浸润性或高危非肌层浸润性膀胱癌患者的管理。